Literature DB >> 2436756

Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study.

G Stoter, R Sylvester, D T Sleijfer, W W ten Bokkel Huinink, S B Kaye, W G Jones, A T van Oosterom, C P Vendrik, P Spaander, M de Pauw.   

Abstract

Univariate and multivariate linear logistic regression analyses of potential prognostic variables have been performed for 163 patients with disseminated nonseminomatous testicular cancer, treated with cisplatin, vinblastine, and bleomycin in a multicenter study of the European Organization for Research on Treatment of Cancer Genito-Urinary Tract Cancer Cooperative Group. With a multivariate analysis, four prognostic groups with complete responder rates of 100, 89, 41, and 18%, respectively, were identified based on three prognostic factors: trophoblastic elements in the primary tumor, serum concentration of alpha-fetoprotein, and lung metastases by size and number. However, with a univariate analysis the logarithm of the beta subunit of human chorionic gonadotrophin (BHCG) was the single most important factor. This model aids the physician in selecting prospectively good risk patients who are candidates for low toxicity chemotherapy and poor risk patients with whom innovative treatment should be attempted.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2436756

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Good-risk-advanced germ cell tumors: historical perspective and current standards of care.

Authors:  Darren R Feldman; Robert J Motzer
Journal:  World J Urol       Date:  2009-06-10       Impact factor: 4.226

2.  Analysis of a non-ras 21-kDa protein in patients with metastatic testicular germ-cell tumors.

Authors:  E Grundner-Culemann; C Bokemeyer; V Neubauer; C Shalitin; H J Schmoll; H Poliwoda; T Benter
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.

Authors:  R N Hitchins; E S Newlands; D B Smith; R H Begent; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

Review 4.  Germ cell tumour chemotherapy.

Authors:  A Horwich
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

5.  Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.

Authors:  M J Seckl; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

6.  Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

Authors:  R de Wit; R Sylvester; C Tsitsa; P H de Mulder; D T Sleyfer; W W ten Bokkel Huinink; S B Kaye; A T van Oosterom; E Boven; K Vermeylen; G Stoter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.

Authors:  R de Wit; G Stoter; D T Sleijfer; S B Kaye; P H de Mulder; W W ten Bokkel Huinink; P J Spaander; M de Pauw; R Sylvester
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

8.  Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.

Authors:  S D Fosså; J P Droz; G Stoter; S B Kaye; K Vermeylen; R Sylvester
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

9.  Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.

Authors:  R de Wit; G Stoter; D T Sleijfer; J P Neijt; W W ten Bokkel Huinink; L de Prijck; L Collette; R Sylvester
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.